Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present MEI Pharma, Inc. (NASDAQ: MEIP).

Full DD Report for MEIP

You must become a subscriber to view this report.


Recent News from (NASDAQ: MEIP)

MEI Pharma Presents Clinical Data from Ongoing Phase 1b Study of ME-401 in Patients with Indolent B-Cell Malignancies at the 2018 American Society of Hematology Annual Meeting
SAN DIEGO , Dec. 2, 2018 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that results from an ongoing Phase 1b study support the complementary potential of intermittent and continuou...
Source: PR Newswire
Date: December, 02 2018 12:00
MEI Pharma Presents Preclinical Data Demonstrating Voruciclib Synergistically Induces Apoptosis in Combination with Venetoclax in Acute Myeloid Leukemia Cells at the 2018 American Society of Hematology Annual Meeting
SAN DIEGO , Dec. 1, 2018 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced preclinical data presented at the 2018 American Society of Hematology (ASH) annual meeting demonstrating that voruci...
Source: PR Newswire
Date: December, 01 2018 12:00
MEI Pharma To Present at Stifel 2018 Healthcare Conference
SAN DIEGO , Nov. 6, 2018 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Daniel P. Gold , Ph.D., the Company's president and chief executive officer, will present a corporate upd...
Source: PR Newswire
Date: November, 06 2018 08:00
MEI Pharma and Kyowa Hakko Kirin Announce License Agreement to Develop and Commercialize ME-401 in Japan
SAN DIEGO , and TOKYO , Nov. 5, 2018 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP) and Kyowa Hakko Kirin Co., Ltd. ( Tokyo : 4151, "Kyowa Hakko Kirin"), today announced the execution of a license agreement granting Kyowa Hakko Kirin exclusive rights to develop and commercialize ME...
Source: PR Newswire
Date: November, 05 2018 08:00
MEI Pharma to Present Clinical Data from Three Oncology Programs at the 2018 American Society of Hematology (ASH) Annual Meeting
SAN DIEGO , Nov. 1, 2018 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that it will present data from three accepted abstracts related to MEI Pharma's clinical stage drug development...
Source: PR Newswire
Date: November, 01 2018 09:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-122.452.572.652.44190,442
2018-12-112.552.462.572.41250,624
2018-12-102.592.522.612.52160,641
2018-12-072.602.642.712.58210,471
2018-12-062.712.602.822.60365,422

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1217,46077,88422.4180Cover
2018-12-1111,73199,37511.8048Cover
2018-12-1026,52984,14131.5292Cover
2018-12-0751,51891,10956.5455Short
2018-12-0672,289153,81046.9989Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on MEIP.


About MEI Pharma, Inc. (NASDAQ: MEIP)

Logo for MEI Pharma, Inc. (NASDAQ: MEIP)

Not available

 

Contact Information

 

 

Current Management

  • Daniel Gold / President, CEO
  • Thomas Zech / CFO, Secretary
  • Pete Despain / IR

Current Share Structure

  • Market Cap: $120,234,911 - 05/17/2018
  • Issue and Outstanding: 37,052,361 - 02/06/2018

 


Recent Filings from (NASDAQ: MEIP)

Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: September, 06 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: September, 05 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: August, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: July, 16 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: June, 18 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: June, 18 2018
Simplified registration form
Filing Type: S-3Filing Source: edgar
Filing Date: June, 06 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 04 2018
Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
Filing Type: DFiling Source: edgar
Filing Date: May, 30 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: May, 29 2018

 

 


Daily Technical Chart for (NASDAQ: MEIP)

Daily Technical Chart for (NASDAQ: MEIP)


Stay tuned for daily updates and more on (NASDAQ: MEIP)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: MEIP)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in MEIP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of MEIP and does not buy, sell, or trade any shares of MEIP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/